Equities

Dawnrays Pharmaceutical (Holdings) Ltd

Dawnrays Pharmaceutical (Holdings) Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.17
  • Today's Change0.00 / 0.00%
  • Shares traded40.00k
  • 1 Year change-12.69%
  • Beta0.4582
Data delayed at least 15 minutes, as of Apr 26 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dawnrays Pharmaceutical (Holdings) Limited is an investment holding company principally engaged in the development, manufacture and sale of non-patented pharmaceutical medicines. The products include intermediate pharmaceutical, bulk medicines and finished drugs. The Company operates its business through two segments. The Intermediates and Bulk Medicines segment is engaged in the manufacture and sale of intermediates and bulk medicines. The Finished Drugs segment is engaged in the manufacture and sale of finished drugs, including antibiotics finished drugs and non-antibiotics finished drugs.

  • Revenue in HKD (TTM)1.24bn
  • Net income in HKD352.35m
  • Incorporated2002
  • Employees1.14k
  • Location
    Dawnrays Pharmaceutical (Holdings) LtdUnits 3001-02, 30/F, CNT Tower, Wanchai Hong KongHKG
  • Phone+852 21119708
  • Fax+852 21119870
  • Websitehttps://www.dawnrays.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CStone Pharmaceuticals501.33m-396.91m1.16bn230.00--2.34--2.31-0.3147-0.31470.39690.38450.28112.443.722,179,688.00-22.25-54.76-48.85-81.6865.60---79.17-301.621.44--0.4431---3.64--59.32------
VIVA Biotech Holdings2.33bn-125.50m1.21bn2.08k--0.300910.010.5195-0.0638-0.06381.201.860.28054.845.131,121,707.00-1.30-1.39-1.79-1.6834.2634.81-4.63-5.441.150.0350.3412---9.4259.3178.03------
TOT Biopharm International Co Ltd843.72m-40.81m1.22bn463.00--1.65321.951.45-0.0563-0.05631.160.96040.58081.877.75---2.81-20.01-3.72-25.2173.5374.74-4.84-68.531.48-4.600.3348--76.5481.8824.36------
Essex Bio-Technology Ltd1.71bn275.26m1.24bn1.48k4.670.64613.710.72830.46890.46892.873.390.61612.283.351,152,300.009.9411.2013.2114.7390.2086.0116.1319.771.46--0.132616.1629.517.7222.113.567.297.39
Jacobio Pharmaceuticals Group Co Ltd68.65m-388.14m1.27bn301.00--1.09--18.45-0.5021-0.50210.08881.470.0419--5.21228,084.70-23.66-45.76-26.86-49.305.04---565.36-372.22----0.1636---33.66--3.43------
Ascletis Pharma Inc61.17m-156.41m1.38bn219.00--0.5763--22.52-0.147-0.1470.0572.360.0222.303.86279,314.70-5.62-6.43-5.91-6.6445.9235.67-255.70-243.3816.54-6.090.0036--4.63-19.3954.04------
Wuhan YZY Biopharma Co Ltd-100.00bn-100.00bn1.44bn123.00-----------------------------------------------------1.50------
Hua Medicine82.80m-228.31m1.68bn177.00--14.23--20.27-0.2336-0.23360.08480.11170.05381.691.98467,804.50-14.84-25.61-17.56-28.8148.78---275.73-1,654.706.06--0.6238--335.31---3.80------
Mabpharm Ltd94.21m-226.28m1.71bn347.00--7.72--18.17-0.0549-0.05490.02280.05370.08930.11766.02271,484.40-21.44-21.42-28.92-27.4986.32---240.19-486.400.7596-19.030.5591--55.87--0.694---26.85--
Immunotech Biopharm Ltd0.00-361.88m1.73bn210.00--9.24-----0.7032-0.70320.000.36470.00----0.00-38.88-37.42-50.88-45.48--------1.03-1.970.4327-------5.25------
Dawnrays Pharmaceutical (Holdings) Ltd1.24bn352.35m1.76bn1.14k4.990.56893.881.410.23440.23440.8282.060.31562.316.371,088,519.008.859.8911.3612.4954.6056.6928.0327.892.2628.890.040535.33-9.903.94-8.951.4163.922.00
Acotec Scientific Holdings Ltd512.14m15.66m2.03bn638.00124.441.4530.933.970.05210.05211.704.470.31360.72133.44802,731.900.9589--1.03--79.65--3.06--9.122.150.1529--19.80---79.35------
Cutia Therapeutics148.75m-2.12bn2.07bn298.00--1.42--13.93-18.26-18.260.7274.80------499,145.20--------51.60---1,426.91--5.38--0.153--1,110.83---253.30------
SinoMab Bioscience Ltd1.48m-262.76m2.07bn233.00--6.16--1,406.03-0.2581-0.25810.00150.30870.0015-------26.20-24.62-32.50-27.7230.92---17,810.33-4,451.74---8.150.604------14.45------
Abbisko Cayman Ltd20.60m-466.46m2.20bn258.00--1.03--106.69-0.7207-0.72070.03183.050.0083--1.4079,846.41-18.74---19.67--100.00---2,264.34------0.0177------12.92------
Laekna Inc0.00-398.62m2.32bn89.00--2.67-----3.30-3.300.002.23------0.00-------------------4.090.0655------52.81------
Data as of Apr 26 2024. Currency figures normalised to Dawnrays Pharmaceutical (Holdings) Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

10.55%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 29 Feb 202494.72m6.31%
UBS Asset Management (Hong Kong) Ltd.as of 29 Dec 202337.04m2.47%
Dimensional Fund Advisors LPas of 04 Apr 202411.85m0.79%
Fidelity Investments Canada ULCas of 29 Feb 20247.79m0.52%
CATAM Asset Management AGas of 31 Mar 20213.23m0.22%
Strategic Advisers LLCas of 29 Feb 20242.41m0.16%
Dimensional Fund Advisors Ltd.as of 29 Feb 2024714.60k0.05%
DFA Australia Ltd.as of 29 Feb 2024222.65k0.02%
Acadian Asset Management LLCas of 29 Feb 2024150.04k0.01%
Schroder Investment Management North America, Inc.as of 30 Jun 2019104.00k0.01%
More ▼
Data from 31 Dec 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.